司普奇拜单抗治疗重度未控制慢性鼻窦炎伴鼻息肉:CROWNS-2随机临床试验
这项在中国51家医院开展的随机双盲3期试验纳入180例重度未控制慢性鼻窦炎伴鼻息肉成人患者,比较司普奇拜单抗与安慰剂(均联用糠酸莫米松鼻喷雾剂)。第24周时,司普奇拜单抗组鼻息肉评分和鼻塞评分较基线的改善均显著优于安慰剂组,严重不良事件少见。
要点
- 第24周鼻息肉评分较基线变化:司普奇拜单抗组-2.6分 vs 安慰剂组-0.3分(最小二乘均值差-2.3,95%CI -2.6至-1.9,P<.001)。
- 第24周鼻塞评分较基线变化:司普奇拜单抗组-1.2分 vs 安慰剂组-0.5分(最小二乘均值差-0.7,95%CI -0.9至-0.5,P<.001)。
- 严重不良事件发生率司普奇拜单抗组2.2% vs 安慰剂组1.1%;关节痛7.8% vs 0%,高尿酸血症5.6% vs 1.1%。
核心结论
- 在每日使用鼻内皮质类固醇的重度慢性鼻窦炎伴鼻息肉患者中,司普奇拜单抗在第24周减小了鼻息肉体积并减轻了鼻部症状严重程度。
研究设计与样本
- 2022年8月9日至2023年4月28日在中国51家医院开展的随机双盲3期临床试验,患者随访于2024年6月25日完成。
- 纳入有全身皮质类固醇使用史或鼻窦手术史、双侧鼻息肉评分5分及以上(0-8分)、每周平均鼻塞评分2分及以上(0-3分)的成人慢性鼻窦炎伴鼻息肉患者。
- 启动糠酸莫米松鼻喷雾剂每侧鼻孔100 µg每日一次治疗4周后,按1:1随机接受皮下司普奇拜单抗300 mg或安慰剂每2周一次共24周,随后两组均接受司普奇拜单抗治疗28周。
- 随机180例患者中179例(平均年龄45岁[SD 12.9];女性61例[34.1%])至少接受1次治疗剂量(司普奇拜单抗组n=90;安慰剂组n=89)。
主要发现
- 总体人群中,第24周鼻息肉评分较基线最小二乘均值变化司普奇拜单抗组-2.6分 vs 安慰剂组-0.3分(最小二乘均值差-2.3;95%CI -2.6至-1.9;P<.001)。
- 嗜酸性粒细胞增多人群中,第24周鼻息肉评分较基线最小二乘均值变化司普奇拜单抗组-3.0分 vs 安慰剂组-0.4分(最小二乘均值差-2.5;95%CI -2.9至-2.1;P<.001)。
- 总体人群中,第24周鼻塞评分较基线最小二乘均值变化司普奇拜单抗组-1.2分 vs 安慰剂组-0.5分(最小二乘均值差-0.7;95%CI -0.9至-0.5;P<.001)。
- 嗜酸性粒细胞增多人群中,第24周鼻塞评分较基线最小二乘均值变化司普奇拜单抗组-1.3分 vs 安慰剂组-0.5分(最小二乘均值差-0.8;95%CI -1.0至-0.6;P<.001)。
- 严重不良事件少见(司普奇拜单抗组2.2% vs 安慰剂组1.1%);关节痛发生率司普奇拜单抗组7.8% vs 安慰剂组0%,高尿酸血症发生率司普奇拜单抗组5.6% vs 安慰剂组1.1%。
关键数值与推荐
- 嗜酸性慢性鼻窦炎伴鼻息肉定义为血嗜酸性粒细胞6.9%及以上(不伴哮喘)或3.7%及以上(伴哮喘),或鼻息肉组织嗜酸性粒细胞每高倍视野55个及以上或27%及以上。
- 鼻息肉评分有临床意义变化阈值为1分及以上,鼻塞评分有临床意义变化阈值为0.5分及以上。
- 共同主要终点为第24周时全部患者和嗜酸性粒细胞增多人群中鼻息肉评分与鼻塞评分较基线的变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chronic rhinosinusitis with nasal polyps causes severe symptoms and impaired quality of life. Stapokibart is a novel monoclonal antibody that targets interleukin 4Rα. OBJECTIVE: To assess the efficacy and safety of stapokibart as an add-on treatment to intranasal corticosteroids in patients with severe uncontrolled chronic rhinosinusitis with nasal polyps. DESIGN, SETTING, AND PARTICIPANTS: From August 9, 2022, to April 28, 2023, this randomized, double-blind, phase 3 clinical trial, conducted at 51 hospitals in China, enrolled adult patients with chronic rhinosinusitis with nasal polyps who had a history of systemic corticosteroid use or sinonasal surgery and a bilateral nasal polyp score of 5 or greater (on a scale of 0-8) and a weekly mean nasal congestion score of 2 or greater (on a scale of 0-3). Eosinophilic chronic rhinosinusitis with nasal polyps was defined as blood eosinophils of 6.9% or greater (without asthma) or 3.7% or greater (with asthma) or an eosinophil count of 55 per high-power field or greater or 27% or greater in nasal polyp tissue. Patient follow-up was completed on June 25, 2024. INTERVENTIONS: Four weeks after initiation of mometasone furoate nasal spray, 100 µg in each nostril daily, patients were randomized to receive subcutaneous stapokibart, 300 mg, or placebo (1:1) every 2 weeks for 24 weeks. Both groups then received stapokibart for 28 weeks. MAIN OUTCOMES AND MEASURES: Co-primary end points were changes from baseline in nasal polyp score (meaningful change threshold [MCT] ≥1 point) and nasal congestion score (MCT ≥0.5 points) at week 24 in all patients and in the population with eosinophilia. RESULTS: Among 180 patients randomized, 179 (mean age, 45 [SD, 12.9] years; 61 [34.1%] women) received at least 1 treatment dose (n = 90 for stapokibart; n = 89 for placebo). In the overall population, the least-squares (LS) mean change in nasal polyp score from baseline to week 24 in the stapokibart vs placebo groups was -2.6 vs -0.3 points, respectively, (LS mean difference, -2.3; 95% CI, -2.6 to -1.9; P < .001); in the population with eosinophilia, the change was -3.0 vs -0.4 points, respectively (LS mean difference, -2.5; 95% CI, -2.9 to -2.1; P < .001). The LS mean change in nasal congestion score from baseline to week 24 in the stapokibart vs placebo groups was -1.2 vs -0.5 points, respectively, in the overall population (LS mean difference, -0.7; 95% CI, -0.9 to -0.5; P < .001) and -1.3 vs -0.5 points, respectively, in the population with eosinophilia (LS mean difference, -0.8; 95% CI, -1.0 to -0.6; P < .001). Serious adverse events were rare (2.2% in the stapokibart group vs 1.1% in the placebo group). Higher rates of arthralgia (7.8% vs 0%) and hyperuricemia (5.6% vs 1.1%) were reported with stapokibart vs placebo, respectively. CONCLUSIONS AND RELEVANCE: Among patients with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal corticosteroid, stapokibart reduced polyp size and severity of nasal symptoms at 24 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05436275.
引用
- Shen S, Yan B, Wang M, et al. Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps: The CROWNS-2 Randomized Clinical Trial. JAMA. 2025. PMID: 40824573. doi:10.1001/jama.2025.12515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。